Entrada Therapeutics (TRDA) Free Cash Flow (2020 - 2026)
Entrada Therapeutics (TRDA) free cash flow from Sep 30, 2020 to Mar 31, 2026. The TTM Entrada Therapeutics (TRDA) free cash flow is -$132M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual Free Cash Flow
Quarterly Free Cash Flow
Entrada Therapeutics (TRDA) Free Cash Flow CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +128.18% |
| 5 Years TTM | +46.20% |
| All Time TTM | +35.66% |
Annual Free Cash Flow change of Entrada Therapeutics (TRDA)
| Year | Free Cash Flow | Change |
|---|---|---|
| 2026 | -$42M | -67.79% |
| 2025 | -$130M | +189.69% |
| 2024 | -$45M | -133.33% |
| 2023 | $134M | -238.80% |
| 2022 | -$97M | +74.39% |
| 2021 | -$55M | +98.78% |
| 2020 | -$28M | N/A |